NMS Menu

Coordinated by GU Ventures
Exploring the How-To of

Commercializing
New Modalities

Can leading organizations collaborate to ensure access to quality resources, engage with complementary organizations, and facilitate access to capital? We believe so!

A Unique Constellation of Life Science Organizations

New Modality Support (NMS) is a collaborative project supporting individual research within the national drug development initiatives OligoNova and CCRM Nordic. It focuses on therapeutic oligonucleotides and advanced therapies (ATMP). The constellation members combine their unique strengths to support early-stage life science companies in the Nordic region.

Learn about the NMS partners
CCRM Nordic, GU Ventures, OligoNova, Sahlgrenska Academy and Sahlgrenska University Hospital
  • CCRM Nordic
  • GU Ventures
  • OligoNova
  • Sahlgrenska Academy
  • Sahlgrenska University Hospital

Voices from New Modality Support

“Utilizing research is crucial. Our researchers’ ideas and solutions can contribute to a better future—if given the opportunity to realize them. NMS plays an important role in achieving this”
Jenny Nyström Dean and Professor of Physiology at the Sahlgrenska Academy, the Medical faculty at University of Gothenburg
“NMS acts as an entrepreneurial catalyst that provides drug development support and serves as a valuable hub of expertise for researchers and their projects as they progress towards clinical application”
Klementina Österberg CEO, GU Ventures
“Although OligoNova and CCRM Nordic operate in relatively different areas and development stages, there are significant opportunities for synergies and collaboration”
Fredrik Wessberg CEO, CCRM Nordic
“Combining and building on our respective skills and strengths will leverage these unique assets to create new and competitive global companies. NMS is a crucial component in this formula and a central resource for the academic drug projects that we support”
Pär Matsson Professor, Sahlgrenska Academy and Scientific Director, OligoNova Hub
“Within the area that NMS addresses, we already have established good relationships with healthcare, industry, and academia. We will build on these to ensure that healthcare and patient perspectives become integral parts of the development of new, advanced drugs.”
Christian Andersson Director of Sahlgrenska ATMP center, Sahlgrenska University Hospital

Sharing Knowledge to Provide Better Support

Success in therapeutic oligonucleotide and ATMP-specific drug development requires new knowledge and understanding. Incorporating research and commercialization strategies early increases a project's chance of success.

Learn more about what we did

Sector Expertise

We simplify the process of collaborating with specialists, including regulatory pathway expertise, as well as finding resources, programs and assistance available to help new and early-stage businesses.

Explore sector expertise

Funding and Investments

Attractive and clear packaging of the investment case is important in order to attract relevant investors. We help early-stage businesses navigate the investor landscape and build strong investor-company relationships.

Explore funding and investments

Fostering Collaboration

NMS helps early-stage businesses in getting access to complementary organizations within the life science ecosystem such as incubators, arenas, hospitals and universities.

Explore collaboration

Want to Learn More?

Learn more about the focus areas of NMS and what we do to support early-stage researchers and innovators.

Read more
 
This is a legacy site from a previous initiative – this project is no longer active. Scroll down to see the website as it was developed. Go back to GU Ventures